Respuesta a largo plazo con rituximab en una paciente con hemofilia adquirida

Jaime García-Chávez, Jorge Vela-Ojeda, Aurora García-Manzano, Abraham Salvador Majluf Cruz

Resultado de la investigación: Contribución a una revistaArtículo

5 Citas (Scopus)

Resumen

A 28 year-old female without history of previous disease. In the seventh month of her first pregnancy she developed hemorrhagic tendency that worsened in the early postpartum period. Activated partial thromboplastin time was 110 sec (control = 35.8 sec) with negative tests for lupus anticoagulant. Factor VIII was <1 % and a factor VIII inhibitor titer was 84 Bethesda Units/mL (BU). Initial therapy included methylprednisolone, prednisone, and cyclophosphamide. After two weeks of treatment, clinical conditions of the patient improved slightly and she was discharged. Outpatient therapy included azathioprine, and prednisone for a period of 22 months but in-hospital management was several times required. We initiated rituximab 375 mg/m2/week/4 weeks. A clinical improvement and increased levels of factors VIII and XI were observed 10 weeks later and factor VIII inhibitor decreased to undetectable levels. After a 82-month follow-up period (since the first rituximab infusion), she is asymptomatic and factor VIII and factor XI plasma levels are 70% and 94%, respectively. FVIII inhibitor level is still undetectable. Rituximab seems an alternative for the treatment of acquired hemophilia refractory to standard treatment.

Idioma originalEspañol
Páginas (desde-hasta)210-212
Número de páginas3
PublicaciónRevista de Investigacion Clinica
Volumen63
N.º2
EstadoPublicada - 1 mar 2011

Huella dactilar

Factor VIII
Hemophilia A
Factor XI
Prednisone
Therapeutics
Lupus Coagulation Inhibitor
Partial Thromboplastin Time
Methylprednisolone
Azathioprine
Cyclophosphamide
Postpartum Period
Outpatients
Rituximab
Pregnancy

Palabras clave

  • Acquired hemophilia
  • Factor IX
  • Factor VIII
  • Hemophilia
  • Rituximab

Citar esto

García-Chávez, Jaime ; Vela-Ojeda, Jorge ; García-Manzano, Aurora ; Majluf Cruz, Abraham Salvador. / Respuesta a largo plazo con rituximab en una paciente con hemofilia adquirida. En: Revista de Investigacion Clinica. 2011 ; Vol. 63, N.º 2. pp. 210-212.
@article{cf4156df5f8a4ce4a3a4729d633f9660,
title = "Respuesta a largo plazo con rituximab en una paciente con hemofilia adquirida",
abstract = "A 28 year-old female without history of previous disease. In the seventh month of her first pregnancy she developed hemorrhagic tendency that worsened in the early postpartum period. Activated partial thromboplastin time was 110 sec (control = 35.8 sec) with negative tests for lupus anticoagulant. Factor VIII was <1 {\%} and a factor VIII inhibitor titer was 84 Bethesda Units/mL (BU). Initial therapy included methylprednisolone, prednisone, and cyclophosphamide. After two weeks of treatment, clinical conditions of the patient improved slightly and she was discharged. Outpatient therapy included azathioprine, and prednisone for a period of 22 months but in-hospital management was several times required. We initiated rituximab 375 mg/m2/week/4 weeks. A clinical improvement and increased levels of factors VIII and XI were observed 10 weeks later and factor VIII inhibitor decreased to undetectable levels. After a 82-month follow-up period (since the first rituximab infusion), she is asymptomatic and factor VIII and factor XI plasma levels are 70{\%} and 94{\%}, respectively. FVIII inhibitor level is still undetectable. Rituximab seems an alternative for the treatment of acquired hemophilia refractory to standard treatment.",
keywords = "Acquired hemophilia, Factor IX, Factor VIII, Hemophilia, Rituximab",
author = "Jaime Garc{\'i}a-Ch{\'a}vez and Jorge Vela-Ojeda and Aurora Garc{\'i}a-Manzano and {Majluf Cruz}, {Abraham Salvador}",
year = "2011",
month = "3",
day = "1",
language = "Espa{\~n}ol",
volume = "63",
pages = "210--212",
journal = "Revista de Investigacion Clinica",
issn = "0034-8376",
publisher = "Instituto Nacional de la Nutricion Salvador Zubiran",
number = "2",

}

García-Chávez, J, Vela-Ojeda, J, García-Manzano, A & Majluf Cruz, AS 2011, 'Respuesta a largo plazo con rituximab en una paciente con hemofilia adquirida', Revista de Investigacion Clinica, vol. 63, n.º 2, pp. 210-212.

Respuesta a largo plazo con rituximab en una paciente con hemofilia adquirida. / García-Chávez, Jaime; Vela-Ojeda, Jorge; García-Manzano, Aurora; Majluf Cruz, Abraham Salvador.

En: Revista de Investigacion Clinica, Vol. 63, N.º 2, 01.03.2011, p. 210-212.

Resultado de la investigación: Contribución a una revistaArtículo

TY - JOUR

T1 - Respuesta a largo plazo con rituximab en una paciente con hemofilia adquirida

AU - García-Chávez, Jaime

AU - Vela-Ojeda, Jorge

AU - García-Manzano, Aurora

AU - Majluf Cruz, Abraham Salvador

PY - 2011/3/1

Y1 - 2011/3/1

N2 - A 28 year-old female without history of previous disease. In the seventh month of her first pregnancy she developed hemorrhagic tendency that worsened in the early postpartum period. Activated partial thromboplastin time was 110 sec (control = 35.8 sec) with negative tests for lupus anticoagulant. Factor VIII was <1 % and a factor VIII inhibitor titer was 84 Bethesda Units/mL (BU). Initial therapy included methylprednisolone, prednisone, and cyclophosphamide. After two weeks of treatment, clinical conditions of the patient improved slightly and she was discharged. Outpatient therapy included azathioprine, and prednisone for a period of 22 months but in-hospital management was several times required. We initiated rituximab 375 mg/m2/week/4 weeks. A clinical improvement and increased levels of factors VIII and XI were observed 10 weeks later and factor VIII inhibitor decreased to undetectable levels. After a 82-month follow-up period (since the first rituximab infusion), she is asymptomatic and factor VIII and factor XI plasma levels are 70% and 94%, respectively. FVIII inhibitor level is still undetectable. Rituximab seems an alternative for the treatment of acquired hemophilia refractory to standard treatment.

AB - A 28 year-old female without history of previous disease. In the seventh month of her first pregnancy she developed hemorrhagic tendency that worsened in the early postpartum period. Activated partial thromboplastin time was 110 sec (control = 35.8 sec) with negative tests for lupus anticoagulant. Factor VIII was <1 % and a factor VIII inhibitor titer was 84 Bethesda Units/mL (BU). Initial therapy included methylprednisolone, prednisone, and cyclophosphamide. After two weeks of treatment, clinical conditions of the patient improved slightly and she was discharged. Outpatient therapy included azathioprine, and prednisone for a period of 22 months but in-hospital management was several times required. We initiated rituximab 375 mg/m2/week/4 weeks. A clinical improvement and increased levels of factors VIII and XI were observed 10 weeks later and factor VIII inhibitor decreased to undetectable levels. After a 82-month follow-up period (since the first rituximab infusion), she is asymptomatic and factor VIII and factor XI plasma levels are 70% and 94%, respectively. FVIII inhibitor level is still undetectable. Rituximab seems an alternative for the treatment of acquired hemophilia refractory to standard treatment.

KW - Acquired hemophilia

KW - Factor IX

KW - Factor VIII

KW - Hemophilia

KW - Rituximab

UR - http://www.scopus.com/inward/record.url?scp=79959927409&partnerID=8YFLogxK

M3 - Artículo

C2 - 21717725

AN - SCOPUS:79959927409

VL - 63

SP - 210

EP - 212

JO - Revista de Investigacion Clinica

JF - Revista de Investigacion Clinica

SN - 0034-8376

IS - 2

ER -